Bay Area genomics startup emerges from stealth with $600M in the bank and promising a '$100 genome' test
When talking about genomics biotechs, financing rounds tend to be more on the modest side — an $18.5 million Series A round for one, $21 million venture equity financing raise for another, and $98 million for Alice Zhang’s Verge Genomics Series B from late last year.
But all of those pale in comparison to a new California genomics outfit, emerging from stealth Tuesday with an eye-popping $600 million from a range of blue-chip investors since its founding in 2016. The name is Ultima Genomics, led by former tech executive Gilad Almogy as both founder and CEO.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.